Last week, Congress passed and the President signed a $1.3 trillion spending package that will keep the government funded through the end of September.
The deal included increased spending for the military, space exploration, and opioid addiction and research programs. The spending plan also included a provision, commonly known as the Rohrabacher-Blumenauer Amendment (RBA) that prohibits the U.S. Department of Justice from using federal funds to prosecute medical marijuana businesses in states that have medical cannabis laws.
With the repeal of the “Cole Memo” by Attorney Jeff Sessions in January, the RBA stands as one of the last protections state’s have against federal interference in their medical marijuana markets. Unfortunately, the RBA is only temporary and does not address states that have legalized recreational adult-use.
Several attempts to settle the issue once and for all have been introduced with bi-partisan support, but have failed each time in the House of Representatives. Rep. Pete Sessions (R-TX), Chairman of the House Rules Committee, has killed a number of bills that would bring the federal policy in line with states that have adopted marijuana policies.
Under the current Administration and with Republican control of Congress, it seems unlikely that a permanent federal solution is near. However, the industry can breathe a slight breath of relief between now and September.